Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 1069   Home Print this page  Email this page Small font size Default font size Increase font size

Year : 2008  |  Volume : 25  |  Issue : 4  |  Page : 172 Table of Contents   

Mesothelioma v/s adenocarcinoma of lung do serum markers help?

Deptt of Respiratory Diseases & Tuberculosis, JLN Medical College, Ajmer (Raj.) 305001, India

Correspondence Address:
Neeraj Gupta
Deptt of Respiratory Diseases & Tuberculosis, JLN Medical College, Ajmer (Raj.) 305001
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0970-2113.45287

Rights and Permissions

How to cite this article:
Gupta N. Mesothelioma v/s adenocarcinoma of lung do serum markers help?. Lung India 2008;25:172

How to cite this URL:
Gupta N. Mesothelioma v/s adenocarcinoma of lung do serum markers help?. Lung India [serial online] 2008 [cited 2021 Feb 26];25:172. Available from: https://www.lungindia.com/text.asp?2008/25/4/172/45287

Going through an enlightening case report of '25 year old male with pleural thickening' by Abhilasha Ahuja et al [1] , the matter of differences between adenocarcinoma of lung & malignant mesothelioma raise many debates.

The diagnosis of malignant mesotheliomas is usually established by a combination of histology & immunohistochemical stains without-resort to electron microscopic examination. However, electron microscopy plays a decisive role in cases with unusual morphology, anomalous histochemical or immuno-histochemical reactions [2] .

Apart from the differences, as described by the authors, between adeno-carcinoma of the lung and mesothelioma, the role of serum markers need further mention. As it may be a case with any cancer in the body, sensitive markers can facilitate early diagnosis and thus early therapeutic intervention.

Soluble Mesothelin Related Protein (SMR) is one such maker which has been studied in Malignant Mesothelioma of pleura and other malignant & non malignant lung and pleural-diseases [3] .

The authors opined that a raised serum SMR concentration is indicative of mesotheliomas with sensitivity of 84% and a specificity of 100%. Other non-mesothelioma tumors that can also cause increased SMR concentrations are ovarian, lung and breast carcinomas, so specificity in studies that include such patients will definitely fall below 100% as was in Scholler and collague's study. [4]

However, one of the salient feature of study by Robinson et al [3] was that none of the seven patients with lung adenocarcinoma in their study had raised SMR concentrations suggesting that this assay might be useful to distinguish the two histologically almost similar conditions.

Moreover, the levels of SMR are related to tumor load. Significantly higher levels were found when the maximum pleural tumor width was more than 3 cm. Higher SMR levels in asbestos exposed individuals also might be a predictor of disease development or a sensitive marker of early disease in some patients [4] .

SMR level estimation is probably the first blood test that is commercially available & may prove an exiting step towards better diagnosis of Mesothelioma and probably to differentiate from adenocarcinoma of lung [5] .

   References Top

1.Ahuja A, Gothi D, Amonkar G, Joshi JM 25 year old male with pleural thickening. Lung India 2008; 25: 82-84.  Back to cited text no. 1    
2.Branscheid D, Krysa S, Bauer E, et al. Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Br J Cardiothorac Surgery 1991; 5: 466-472.  Back to cited text no. 2    
3.Robinson Bruce WS, Creaney J, Lake R, Nowak Anna et al. Mesothelinfamily proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-16.  Back to cited text no. 3    
4.Scholler N, Fu N, Yang Y et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proct Natt Acad Sic USA 1999; 96: 11531-36.  Back to cited text no. 4    
5.West SD, Lee Y. C. Gary. Management of malignant pleural mesothelioma. Clin Chest Med 2006; 27.335-354.  Back to cited text no. 5    


    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded285    
    Comments [Add]    

Recommend this journal